| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC9595 | E-4031 Featured | E-4031 is a benzenesulfonamide antiarrhythmic agent; blocks the ATP-sensitive potassium channel. |
|
| DC8533 | E5555 hydrobromide | E5555 shows potent inhibitory effects on human platelet aggregation induced by thrombin and TRAP with IC values of 0.064 and 0.031 μM respectively. |
|
| DC10141 | E6005 Featured | E6005 potently and selectively inhibited human PDE4 activity with an IC50 of 2.8 nM and suppressed the production of various cytokines from human lymphocytes and monocytes with IC50 values ranging from 0.49 to 3.1 nM. |
|
| DC8485 | E-64d(Aloxistatin) Featured | E-64D is an inhibitor of cathepsins B and L; also thought to inhibit calpain,showed a potent activity for COVID-19(SARS-COV-2)with EC50: MERS-COV(1.275),SARS-COV(0.760) |
|
| DC10563 | E-7046 Featured | E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities. |
|
| DC5065 | Golvatinib (E7050) Featured | E-7050 is hepatocyte growth factor receptors (HGFR). |
|
| DC7116 | E7080 (Lenvatinib) Featured | E7080 (Lenvatinib; Vargatef) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β. |
|
| DC11062 | E7107 | E7107 (E-7107) is a derivative of pladienolide that targets the SF3b subunit of the spliceosome, shows significant antitumor activity in vitro and in vivo. |
|
| DC9983 | E-7449 Featured | E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2; enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors. |
|
| DCAPI1441 | Seocalcitol | EB1089 is an analog of 1,25 dihydroxyvitamin D which acts as a vitamin D receptor (VDR). EB1089 is noted to reverse hypercalcemia and is a potent inhibitor of PTH-rP (parathyroid hormone-related peptide, PTHRP) in vitro. In studies utilizing a squamous ca |
|
| DC10939 | Edasalonexent | Edasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA). |
|
| DC11398 | Edicotinib（JNJ-40346527） Featured | Edicotinib（JNJ-40346527）is a small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity. |
|
| DC8305 | Edoxaban Featured | Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention |
|
| DC8793 | Edoxaban tosylate monohydrate Featured | Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention |
|
| DCAPI1479 | Efavirenz | Efavirenz is a nonnucleoside HIV-1 reverse transcriptase (RT) inhibitor which selectively inhibits the glucuronidation of 3'-Azido-3'-deoxythymidine β-D-glucuronide, Sodium Salt. Studies suggest that Efavirenz binds to a distinct site of reverse transcrip |
|
| DC9755 | eFT508(Tomivosertib) Featured | Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance. |
|
| DC10182 | Elacestrant (dihydrochloride) Featured | Elacestrant dihydrochloride (RAD1901 dihydrochloride) is a selective and orally available estrogen receptor (ERR) degrader with IC50 values of 48 and 870 nM for ERα and ERβ, respectively. |
|
| DC8301 | Elacridar Featured | Elacridar is an orally selectly potent P-glycoprotein (P-gp/ABCG1) inhibitor. |
|
| DC11192 | Elacytarabine | Elacytarabine (CP-4055, CP4055) is a fatty acid derivative of cytarabine with potential antineoplastic activity. |
|
| DC11551 | Elenbecestat Featured | Elenbecestat (E2609) is a novel potent, oral BACE1 inhibitor for treatment of Alzheimer's disease.. |
|
| DC3156 | Elesclomol (STA-4783) Featured | Elesclomol (STA-4783) is a novel potent oxidative stress inducer that illicits pro-apoptosis events among tumor cells.. |
|
| DC8323 | Eletriptan HBr Featured | Eletriptan HBr is an orally active, selective 5-HT1B/1D receptor agonist. |
|
| DC7772 | Elinogrel | Elinogrel is a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. |
|
| DC8268 | Eliprodil Featured | Eliprodil is a non-competitive NMDA receptor antagonist that acts at the polyamine modulatory site. |
|
| DC8626 | Eluxadoline Featured | Eluxadoline is an orally active mixed μ opioid receptor (μOR) agonist δ opioid receptor (δOR) antagonist. |
|
| DC10869 | Olodanrigan(EMA401) Featured | EMA401(Olodanrigan) is a highly selective AT2R antagonist, inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons. |
|
| DC11028 | EMD-281014 hydrochloride | EMD-281014 hydrochloride is a potent, highly selective 5-HT2A antagonist with Ki of 0.87 nM, displays little to no affinity for 5-HT2C receptors (Ki=557 nM), human D2 receptors and IKr channels. |
|
| DC11027 | EMD-281014 | EMD-281014 is a potent, highly selective 5-HT2A antagonist with Ki of 0.87 nM, displays little to no affinity for 5-HT2C receptors (Ki=557 nM), human D2 receptors and IKr channels. |
|
| DC9771 | ACU4429,ACU 4429,ACU-4429 Featured | Emixustat hydrochloride strongly inhibits 11-cis-retinol production with IC50 values of 232 ± 3 nM. |
|
| DC10314 | Emixustat | Emixustat, a novel visual cycle modulator, is an inhibitor of the visual cycle isomerase with an IC50 value of 4.4 nM in vitro. |
|
